Madrigal Pharmaceuticals, Inc.
MDGL
$421.90
$9.672.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -281.90M | -391.59M | -465.89M | -518.67M | -510.45M |
| Total Depreciation and Amortization | 1.53M | 1.36M | 1.10M | 875.00K | 712.00K |
| Total Amortization of Deferred Charges | 1.77M | 1.87M | 2.09M | 2.36M | 2.55M |
| Total Other Non-Cash Items | 82.21M | 80.51M | 79.48M | 76.60M | 71.82M |
| Change in Net Operating Assets | -111.02M | -87.46M | -72.35M | 7.82M | -13.59M |
| Cash from Operations | -307.41M | -395.31M | -455.57M | -431.02M | -448.96M |
| Capital Expenditure | -974.00K | -1.11M | -1.46M | -2.30M | -1.86M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -37.63M | -207.46M | -272.92M | -586.26M | -334.11M |
| Cash from Investing | -38.61M | -208.56M | -274.39M | -588.56M | -335.97M |
| Total Debt Issued | -- | -- | -- | 0.00 | 15.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 37.61M | 170.00M | 735.06M | 1.20B | 1.19B |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | -75.00K |
| Cash from Financing | 37.61M | 170.00M | 735.06M | 1.20B | 1.21B |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -308.40M | -433.87M | 5.10M | 175.63M | 422.40M |